Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trialNeyssa Marina, Lisa A. Teot, Heike E. Daldrup‐Link et al.|The Lancet Oncology|2016Cited by 537
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled TrialStefan Bielack, Mark L. Bernstein, Sigbjørn Smeland et al.|Journal of Clinical Oncology|2015Cited by 419
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trialAndrew R. Clamp, Jonathan A. Ledermann, Elizabeth C James et al.|The Lancet|2019Cited by 223
ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysisA. Clamp, Jonathan A. Ledermann, Iain A. McNeish et al.|Annals of Oncology|2017Cited by 51
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trialSarah P. Blagden, Andrew R. Clamp, Adrian Cook et al.|The Lancet Oncology|2020Cited by 37